Gennex Lab.

Which are the latest news on Gennex Lab.?

Why is Gennex Laboratories Ltd falling/rising?

As of 05-Sep, Gennex Laboratories Ltd's stock price is rising to 12.12, reflecting a 2.71% increase after a trend reversal following five days of decline. The stock has outperformed its sector and shows strong long-term positioning despite a drop in investor participation.

As of 05-Sep, Gennex Laboratories Ltd's stock price is rising, currently at 12.12, with a change of 0.32 (2.71%) upwards. This increase comes after a trend reversal, as the stock has gained after five consecutive days of decline. Additionally, the stock has outperformed its sector by 2.82% today, indicating a positive performance relative to its peers.<BR><BR>Despite a recent decline in investor participation, with delivery volume falling by 71.46% against the 5-day average, the stock remains above its 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a generally strong position in the longer term. The stock's performance over the past month shows a significant increase of 35.12%, contrasting with a decline in the benchmark Sensex by 2.44% during the same period. This strong monthly performance likely contributes to the current rise in stock price.

Who are in the management team of Gennex Lab.?

The management team of Gennex Lab includes Arihant Baid (Chairman & Managing Director), T M GopalaKrishnan (Whole-time Director), and five Independent Directors: Y Ravinder Reddy, Sadhana Bhansali, A S Nageswar Rao, and A Ranga Rao Pantulu.

The management team of Gennex Lab includes the following individuals:<BR><BR>1. **Arihant Baid** - Chairman & Managing Director<BR>2. **T M GopalaKrishnan** - Whole-time Director<BR>3. **Y Ravinder Reddy** - Independent Director<BR>4. **Sadhana Bhansali** - Independent Director<BR>5. **A S Nageswar Rao** - Independent Director<BR>6. **A Ranga Rao Pantulu** - Independent Director<BR><BR>If you need more information about their roles or contributions, feel free to ask!

What does Gennex Lab. do?

Gennex Laboratories Ltd is a micro-cap manufacturer and exporter of active pharmaceutical ingredients and intermediates, incorporated in 1985 and known for its recent quarterly net sales of 40 Cr and net profit of 4 Cr as of June 2026. The company has a market cap of INR 313 Cr and key financial metrics include a P/E of 16.00 and a debt-equity ratio of 0.12.

Overview:<BR>Gennex Laboratories Ltd is a leading manufacturer and exporter of active pharmaceutical ingredients and intermediates in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Gennex Laboratories Ltd was incorporated on June 25, 1985, and was formerly known as Prudential Pharmaceuticals Limited. The company converted into a Public Limited Company and changed its name in 2007. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 40 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 4 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 313 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 16.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.12 <BR>Return on Equity: 8.61% <BR>Price to Book: 1.41 <BR><BR>Contact Details:<BR>Address: Survey No 133 Bollaram, Jinnaram Mandal Medak Telangana : 502325 <BR>Tel: 91-8458-279406/279516 <BR>Website: http://www.gennexlab.com

Who are the peers of the Gennex Lab.?

Gennex Lab.'s peers include Transchem, Medico Remedies, Medicamen Biotec, Ambalal Sarabhai, Trident Lifeline, BDH Industries, Astonea Labs, Zenotech Lab., and Everest Organics. Gennex Lab. has average management risk and growth, with a 1-year return of 6.23%, significantly lower than Transchem's 604.40% but higher than Everest Organics' -30.60%.

Peers: The peers of Gennex Lab. are Transchem, Medico Remedies, Medicamen Biotec, Ambalal Sarabhai, Trident Lifeline, BDH Industries, Astonea Labs, Zenotech Lab., and Everest Organics.<BR><BR>Quality Snapshot: Excellent management risk is observed at Medico Remedies and BDH Industries, while Average management risk is found at Transchem, Medicamen Biotec, Trident Lifeline, Gennex Lab., Astonea Labs, and Zenotech Lab. Below Average management risk is noted at Ambalal Sarabhai and Everest Organics. Growth is Excellent at Trident Lifeline, Good at Medico Remedies and Astonea Labs, Average at Gennex Lab., Transchem, and the rest, while Below Average growth is seen at Medicamen Biotec, Ambalal Sarabhai, Zenotech Lab., and Everest Organics. Capital Structure is Excellent at Gennex Lab. and BDH Industries, Good at Medico Remedies and Trident Lifeline, Average at Ambalal Sarabhai, and Below Average at Astonea Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Transchem at 604.40%, while the lowest is Everest Organics at -30.60%. Gennex Lab.'s 1-year return is 6.23%, which is significantly lower than Transchem's but higher than Everest Organics. Additionally, the six-month return is negative for Everest Organics, Medicamen Biotec, and BDH Industries.

How big is Gennex Lab.?

As of 31st August, Gennex Laboratories Ltd has a market capitalization of 313.00 Cr, with net sales of 183.06 Cr and a net profit of 18.33 Cr reported in the latest four quarters.

As of 31st August, Gennex Laboratories Ltd has a market capitalization of 313.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Gennex Laboratories Ltd reported net sales of 183.06 Cr and a net profit of 18.33 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 186.69 Cr and total assets of 255.86 Cr.

Should I buy, sell or hold Gennex Laboratories Ltd?

When is the next results date for Gennex Laboratories Ltd?

The next results date for Gennex Laboratories Ltd is 14 August 2026.

The next results date for Gennex Laboratories Ltd is scheduled for 14 August 2026.

Are Gennex Laboratories Ltd latest results good or bad?

Gennex Laboratories Ltd's latest results show strong revenue growth with a 51.15% increase in net sales, but profitability concerns arise from a significant drop in operating margins to 9.66% and a 28.63% decrease in net profit quarter-on-quarter. Overall, while sales are up, the decline in margins and profits raises questions about the company's financial health.

Gennex Laboratories Ltd's latest results present a mixed picture. On one hand, the company achieved a significant year-on-year increase in net sales, which surged by 51.15% to ₹60.96 crores, marking the highest quarterly revenue in its recent history. This strong top-line growth indicates robust demand for its products.<BR><BR>However, the results also reveal serious concerns regarding profitability. Operating margins, excluding other income, fell sharply to 9.66% from 23.61% in the same quarter last year, reflecting a substantial margin compression of 1,395 basis points. This decline raises questions about the company's cost management and pricing strategies, especially as net profit decreased by 28.63% quarter-on-quarter, despite a year-on-year increase of 61.21%.<BR><BR>Overall, while the revenue growth is impressive, the significant drop in operating margins and sequential profit decline suggest that Gennex may be facing underlying challenges that could impact its long-term sustainability and investor confidence. Therefore, the results can be viewed as concerning, particularly regarding profitability.

How has been the historical performance of Gennex Lab.?

Gennex Lab has demonstrated significant growth in net sales and profitability, with net sales increasing from 55.62 Cr in Mar'20 to 137.90 Cr in Mar'25, and profit after tax rising from 1.86 Cr to 18.12 Cr in the same period, despite rising raw material costs and negative cash flow in recent years. Total assets grew from 56.94 Cr to 255.86 Cr, indicating strong overall financial expansion.

Answer:<BR>The historical performance of Gennex Lab shows significant growth in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Gennex Lab's net sales have increased from 55.62 Cr in Mar'20 to 137.90 Cr in Mar'25, demonstrating a consistent upward trend. Total operating income has mirrored this growth, rising from 55.62 Cr in Mar'20 to 137.90 Cr in Mar'25. However, the raw material costs have also escalated, reaching 100.59 Cr in Mar'25 from 34.19 Cr in Mar'21. Despite rising costs, the operating profit (PBDIT) has shown improvement, climbing to 27.14 Cr in Mar'25 from 4.20 Cr in Mar'20. Profit before tax has also increased significantly, reaching 21.40 Cr in Mar'25 compared to 2.55 Cr in Mar'20. The profit after tax has followed suit, growing from 1.86 Cr in Mar'20 to 18.12 Cr in Mar'25. The company's total assets have expanded from 56.94 Cr in Mar'20 to 255.86 Cr in Mar'25, while total liabilities have increased from 56.94 Cr to 10.22 Cr in the same period. Cash flow from operating activities has been negative in recent years, with a cash outflow of 10.00 Cr in Mar'25, contrasting with a positive cash flow of 23.00 Cr in Mar'23. Overall, Gennex Lab has shown robust growth in sales and profitability, despite challenges in managing costs and cash flow.

Is Gennex Lab. overvalued or undervalued?

As of November 7, 2025, Gennex Lab's valuation is considered attractive with a PE ratio of 19.66, favorable compared to peers like Sun Pharma and Divi's Lab, and despite recent underperformance, it has shown strong long-term growth of 296.11% over five years.

As of 7 November 2025, Gennex Lab's valuation grade has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. The PE ratio stands at 19.66, the EV to EBIT ratio is 15.54, and the EV to EBITDA ratio is 13.64. <BR><BR>In comparison to its peers, Gennex Lab's valuation is more favorable than Sun Pharma, which has a PE ratio of 35.17, and Divi's Lab, which is significantly more expensive at a PE of 71.11. Other peers like Cipla and Dr. Reddy's Labs have PE ratios of 22.33 and 17.43, respectively, indicating that Gennex Lab is positioned competitively within the industry. Despite recent underperformance relative to the Sensex, particularly over the past year, the long-term returns of 296.11% over five years suggest a strong growth trajectory, reinforcing its current valuation stance.

Who are the top shareholders of the Gennex Lab.?

The top shareholders of Gennex Lab are Premier Fiscal Services Private Limited with 16.5%, Jms Mines & Minerals Private Limited at 3.47%, and individual investors who collectively own 62.19%. There are no holdings from mutual funds or foreign institutional investors.

The top shareholders of Gennex Lab include Premier Fiscal Services Private Limited, which holds the highest stake among promoters at 16.5%. Additionally, Jms Mines & Minerals Private Limited is the highest public shareholder with a holding of 3.47%. Individual investors collectively own 62.19% of the company. It's also noteworthy that there are no holdings from mutual funds or foreign institutional investors.

What is the technical trend for Gennex Lab.?

As of May 12, 2025, Gennex Lab's trend is mildly bearish, with daily moving averages and Bollinger Bands indicating bearishness, while mixed signals from MACD and KST suggest caution in the near term.

As of 12 May 2025, the technical trend for Gennex Lab has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearishness and the Bollinger Bands showing a bearish trend on both weekly and monthly time frames. While the weekly MACD and KST are mildly bullish, the overall monthly indicators, including MACD and KST, remain mildly bearish, suggesting a lack of strong upward momentum. The Dow Theory shows a mildly bullish signal on the weekly chart but no trend on the monthly, indicating mixed signals. Overall, the strength of the bearish trend is moderate, with key indicators pointing towards caution in the near term.

Has Gennex Lab. declared dividend?

No Dividend History Available